Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 30;11:4413–4429. doi: 10.2147/OTT.S162255

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Xue et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Zyflamend inhibited cell survival of UBC cells and suppressed NFκB signaling pathway.

Notes: (A) Cell viability of UBC cells treated with Zyflamend at various concentrations (0–1,200 μg/mL) for 72 h detected by MTT assay. Data are presented as mean ± SE. Western blotting analysis on T24, T24R, and J82 cells treated with the indicated concentrations of Zyflamend for the expression levels of NFκB transcriptional factor (B). The graphs depict the quantification data of Western blotting on pRelA and total RelA, which were analyzed by ImageJ software. The NFκB downstream targets related to cell proliferation (C), survival (D), and invasion/angiogenesis (E) were also examined after 48 h treatment with Zyflamend.

Abbreviations: UBC, urinary bladder cancer; NFκB, nuclear factor kappaB; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; SE, standard error; T24R, cisplatin-resistant T24 cell; RQ, relative quantification.